Strongest evidence: The most robust research supports vitamin E for reducing liver enzymes in people with non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD). For aspartate aminotransferase (AST), 3 of 5 studies reported beneficial effects (moderate evidence strength), with effective doses of 298–1000 IU/day. For alanine aminotransferase (ALT), all 4 studies showed benefit (moderate evidence), with doses of 400–1000 IU/day. Effects were typically observed at 8–12 weeks. Evidence for reducing inflammation is also moderate, with all 3 studies reporting benefit, though effect sizes varied widely (small to large) and doses were inconsistent.
Mixed or weaker evidence: Several outcomes have low or very low evidence strength, meaning conclusions are preliminary. For pain reduction, all 3 studies reported benefit (low evidence), but one combined vitamin E with other nutrients, making its independent effect unclear. For sperm morphology, only 1 of 3 studies found a significant benefit (low evidence). For tumor necrosis factor alpha (TNF-α) and malondialdehyde levels, only 1 of 3 studies each showed a significant effect, with the rest neutral. For sperm motility, all 3 studies found no benefit (very low evidence).
Effective dose patterns: Across multiple outcomes, effective doses converge in the range of 400–1000 IU/day for liver-related outcomes (AST, ALT) and 400–800 IU/day for TNF-α reduction. For pain, one study used 600 mg twice daily. For sperm morphology, doses of 100 mg twice or thrice daily were used. No consistent dose was reported for inflammation or malondialdehyde reduction.
Population insights: The strongest evidence is concentrated in people with NAFLD or MASLD, where vitamin E shows consistent benefits for liver enzyme reduction. Other clinical populations studied include patients with carpal tunnel syndrome, NASH, epilepsy, and male infertility. Evidence in healthy individuals is minimal, and most findings come from specific clinical groups, limiting generalizability.
Notable caveats: Across syntheses, several caveats recur: small evidence bases (3–5 studies per outcome), potential publication bias (especially for outcomes where all studies show benefit), and many individual studies failing to reach statistical significance. Several outcomes rely on studies that combined vitamin E with other nutrients, making its independent effect uncertain. Effect sizes vary widely, and most findings are preliminary.